GenesisCare signs MoU for Versa HD cancer treatment systems and research agreement with Elekta
Australia and Europe’s largest private provider of cancer care expands investment in Elekta’s innovative radiation therapy solutions and investigates potential to treat benign diseasesSTOCKHOLM, November 14, 2018 – Elekta (EKTA-B.ST) announced today that GenesisCare has signed a Memorandum of Understanding (MoU) for Elekta Versa HD™ linear accelerators (linacs) to deliver radiation therapy across its growing network of oncology centers in Australia, the UK, Spain, and soon in China and South East Asia. It is valued at approximately USD 60 million. The MoU includes provisions for Elekta’s